Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94430ArticlesСтатьиResearch ArticleDipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes mellitusИнгибиторы дипептидилпептидазы-4 при лечении сахарного диабета типа 2MorgunovaT. BМоргуноваТатьяна Борисовна

канд. мед. наук, доц. каф. эндокринологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова

tanmorgun@mail.ruFadeevV. VФадеевВалентин Викторович

д-р мед. наук, зав. каф. эндокринологии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России15042016184VOL 18, NO4 (2016)ТОМ 18, №4 (2016)202328122021Copyright ©; 2016, Consilium MedicumCopyright ©; 2016, ООО "Консилиум Медикум"2016Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94430

Type 2 diabetes mellitus is one of the most common endocrine diseases. This article discusses the new classes of antihyperglycemic agents (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors), the approaches for prescription these drugs. The article also discusses the cardiovascular safety of new antihyperglycemic agents.

Сахарный диабет типа 2 - одно из наиболее часто встречающихся эндокринных заболеваний. В статье обсуждаются новые классы сахароснижающих препаратов (ингибиторы дипептидилпептидазы-4, агонисты рецепторов глюкагоноподобного пептида-1, ингибиторы натрий-глюкозного котранспортера-2), подходы к их назначению. Также рассматриваются вопросы кардиоваскулярной безопасности современных сахароснижающих препаратов.

type 2 diabetes mellitusantihyperglycemic agentsdipeptidyl peptidase 4 inhibitorsсахарный диабет 2 типасахароcнижающие препаратылечениеингибиторы дипептидилпептидазы-4Godinho R, Mega C, Teixeira de Lemos E et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res 2015; 2015: 806979. Doi: 10.1155/2015/806979. Epub 2015 May 17. Review.Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой (7-й выпуск). Сахарный диабет. 2015; 18 (1S): 1-112.Inzucchi S.E, Bergenstal R.M, Buse J.B et al. Management of hyperglycemia in type 2 diabetes: a patient - centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp Opin Pharmacother 2014; 15 (6): 851-63. Doi: 10.1517/14656566.2014.898750.Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513-27.Pratley R.E, Kipnes M.S, Fleck P.R et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167-76.Pratley R.E, Reusch J.E, Fleck P.R et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo - controlled study. Curr Med Res Opin 2009; 25: 2361-71.Rosenstock J, Rendell M.S, Gross J.L et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145-52.Nauck M.A, Ellis G.C, Fleck P.R et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double - blind, placebo - controlled study. Int J Clin Pract 2009; 63: 46-55.Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab 2014; 16 (12): 1239-46. Doi: 10.1111/dom.12377. Epub 2014 Sep 25.De Fronzo R.A, Fleck P.R, Wilson C.A, Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double - blind, placebo - controlled study. Diabetes Care 2008; 31: 2315-7.Stratton I.M, Adler A.I, Neil H.A et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2010; 321: 405-12.UKPDS Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.Gerstein H.C, Miller M.E, Byington R.P et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.Kahn S.E, Haffner S.M, Heise M.A et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427-43.Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2- year study. Int J Clin Pract 2010; 64 (5): 562-76. Doi: 10.1111/j.1742- 241.2010.02353.x.Göke R, Bader G, Dworak M. Real - life effectiveness and tolerability of vildagliptin and other oral glucose - lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther 2014; 5 (1): 183-91. Doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double - blind, non - inferiority trial. Lancet 2012; 380 (9840): 475-83. Doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.Matthews D.R, Dejager S, Ahren B et al. Vildagliptin add - on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780-9. Doi: 10.1111/j.1463-1326.2010.01233.x.Mishriky B.M, Cummings D.M, Tanenberg R.J. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add - on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta - analysis. Diabetes Res Clin Pract 2015; 109 (2): 378-88. Doi: 10.1016/j.diabres.2015.05.025. Epub 2015 May 14. Review.FDA Guidance for Industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdfWhite W.B, Cannon C.P, Heller S.R et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35.